Nucleotide structure and expression of equine pigment epithelium-derived factor during repair of experimentally induced wounds in horses

American Journal of Veterinary Research

Volumn 70, Issue 1, 2009, Pages 112-117

  Ipiña, Zoë ^a,b   Lussier, Jacques G ^a   Theoret, Christine L ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b COGEBY ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA; NUCLEOTIDE; PIGMENT EPITHELIUM DERIVED FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA LIBRARY; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GRANULATION TISSUE; HORSE; LIMB INJURY; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SKIN BIOPSY; SKIN INJURY; WOUND HEALING;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CLONING, MOLECULAR; EYE PROTEINS; FEMALE; GENE EXPRESSION; HORSES; MOLECULAR SEQUENCE DATA; NERVE GROWTH FACTORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; SEQUENCE ALIGNMENT; SERPINS; WOUND HEALING;

ANIMALIA; EQUIDAE;

EID: 58549087386     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.70.1.112     Document Type: Article

References (33)

1. Jacobs KA, Leach DH, Fretz PB, et al. Comparative aspects of the healing of excisional wounds on the leg and body of horses. Vet Surg 1984;13:83-90.
2. Knottenbelt DC. Equine wound management: are there significant differences in healing at different sites on the body? Vet Dermatol 1997;8:273-290.
3. Perkins NR, Reid SW, Morris RS. Profiling the New Zealand Thoroughbred racing industry. 2. Conditions interfering with training and racing. N Z Vet J 2005;53:69-76.
4. Wilmink JM, van Weeren PR, Stolk PW, et al. Differences in second-intention wound healing between horses and ponies: histological aspects. Equine Vet J 1999;31:61-67.
5. Wilmink JM, Veenman JN, van den Boom R, et al. Differences in polymorphonucleocyte function and local inflammatory response between horses and ponies. Equine Vet J 2003;35:561-569.
6. Theoret CL, Barber SM, Moyana TN, et al. Expression of transforming growth factor β1, β3, and basic fibroblast growth factor in full-thickness skin wounds of equine limbs and thorax. Vet Surg 2001;30:269-277.
7. Theoret CL, Barber SM, Moyana TN, et al. Preliminary observations on expression of transforming growth factor β1, β3, and basic fibroblast growth factor in equine limb wounds healing normally or with proud flesh. Vet Surg 2002;31:266-273.
8. van den Boom R, Wilmink JM, O'Kane S, et al. Transforming growth factor-beta levels during second-intention healing are related to the different course of wound contraction in horses and ponies. Wound Repair Regen 2002;10:188-194.
9. Schwartz AJ, Wilson DA, Keegan KG, et al. Factors regulating collagen synthesis and degradation during second-intention healing of wounds in the thoracic region and the distal aspect of the forelimb of horses. Am J Vet Res 2002;63:1564-1570.
10. Lepault E, Céleste C, Doré M, et al. Comparative study on microvascular occlusion and apoptosis in body and limb wounds in the horse. Wound Repair Regen 2005;13:520-529.
11. Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol 2001;61:253-270.
12. Braun S, Hanselmann C, Gassmann MG, et al. Nrf2, transcription factor, a novel target of keratinocyte growth factor action which regulates gene expression and inflammation in the healing skin wound. Mol Cell Biol 2002;22:5492-5505.
13. Si Z, Bhardwaj R, Rosch R, et al. Impaired balance of type I and type III procollagen mRNA in cultured fibroblasts of patients with incisional hernia. Surgery 2002;131:324-331.
14. Lefebvre-Lavoie J, Lussier JG, Theoret CL. Profiling of differentially expressed genes in wound margin biopsies of horses using suppression subtractive hybridization. Physiol Genomics 2005;22:157-170.
15. Ren J-G, Jie C, Talbot C. How PEDF prevents angiogenesis: a hypothesized pathway. Med Hypotheses 2005;64:74-78.
16. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999;285:245-248.
17. Volpert OV, Zaichuk T, Zhou W, et al. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 2002;8:349-357.
18. Tombran-Tink J, Barnstable CJ. Therapeutic prospects for PEDF: more than a promising angiogenesis inhibitor. Trends Mol Med 2003;9:244-250.
19. Zhang SX, Wang JJ, Gao G, et al. Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor. FASEB J 2006;20:323-325.
20. Wang JJ, Zhang SX, Mott R, et al. Salutary effect of pigment epithelium-derived factor in diabetic nephropathy: evidence for antifibrogenic activities. Diabetes 2006;55:1678-1685.
21. Lévesque V, Fayad T, Ndiaye K, et al. Size-selection of cDNA libraries for the cloning of cDNAs after suppression subtractive hybridization. Biotechniques 2003;35:72-78.
22. Bédard J, Brule S, Price CA, et al. Serine protease inhibitor-E2 (SERPINE2) is differentially expressed in granulosa cells of dominant follicle in cattle. Mol Reprod Dev 2003;64:152-165.
23. Ndiaye K, Fayad T, Silversides DW, et al. Identification of down-regulated messenger RNAs in bovine granulosa cells of dominant follicles following stimulation with human chorionic gonadotropin. Biol Reprod 2005;73:324-333.
24. Tombran-Tink J. The neuroprotective and angiogenesis inhibitory serpin, PFDF: new insights into phylogeny, function, and signalling. Front Biosci 2005;1:2131-2149.
25. Singh VK, Chader GJ, Rodriguez IRL. Structural and comparative analysis of the mouse gene for pigment epithelium-derived factor (PEDF). Mol Vis 1998;4:7-12.
26. Becerra SP, Sagasti A, Spinella P, et al. Pigment epithelium-derived factor behaves like a noninhibitory serpin. Neurotrophic activity does not require the serpin reactive loop. J Biol Chem 1995;270:25992-25999.
27. Petersen SV, Valnickova Z, Enghild JJ. Pigment-epithelium-derived factor (PEDF) occurs at a physiologically relevant concentration in human blood: purification and characterization. Biochem J 2003;374:199-206.
28. Takenaka K, Yamagishi S, Jinnouchi Y, et al. Pigment epithelium-derived factor (PEDF)-induced apoptosis and inhibition of vascular endothelial growth factor (VEGF) expression in MG63 human osteosarcoma cells. Life Sci 2005;77:3231-3241.
29. Aparicio S, Sawant S, Lara N, et al. Expression of angiogenesis factors in human umbilical vein endothelial cells and their regulation by PEDF. Biochem Biophys Res Commun 2005;326:387-394.
30. Francis MK, Appel S, Meyer C, et al. Loss of EPC1/PEDF expression during skin aging in vivo. J Invest Dermatol 2004;122:1096-1105.
31. Spranger J, Osterhoff M, Reimann M, et al. Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes 2001;50:2641-2645.
32. Holekamp NM, Bouck N, Volpert O. Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration. Am J Ophthalmol 2002;134:220-227.
33. Pignolo RJ, Francis MK, Rotenberg MO, et al. Putative role for EPC-1/ PEDF in the G0 growth arrest of human diploid fibroblasts. J Cell Physiol 2003;195:12-20.